GlaxoSmithKline (GSK) MIsses Q1 EPS Views on Lighter Revs

GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of $0.42, $0.49 worse than the analyst estimate of $0.91. Revenue for the quarter came in at $10.49 million versus the consensus estimate of $10.88 million.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins